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Abstract 
Purpose: To determine the effects of sevoflurane on NPC-039 nasopharyngeal carcinoma cells. 
Methods: WST-8 assays and flow cytometry with annexin V/PI staining were used to analyze the 
effects of sevoflurane on growth and induction of apoptotic changes in NPC-039 cells. Cell viability was 
performed on a microplate reader. 
Results: Treatment of NPC-039 cells with 4 – 10 µM sevoflurane significantly inhibited cell growth (p < 
0.005) with a median inhibitory concentration of 6 μM. NPC-039 cells incubated with sevoflurane 
showed prominent nuclear fragmentation and chromatin condensation. NPC-039 cells that exhibited 
apoptotic symptoms increased from 23.34 to 56.77 % when duration of treatment was increased from 
24 to 48 h. Sevoflurane-treated cells also expressed increased levels of Bax and cleaved caspase-3. 
Reactive oxygen species formation was also higher in sevoflurane-treated NPC-039 cells than in 
control. Pre-treatment with Z-VAD-FMK followed by incubation with sevoflurane partly reduced the 
population of apoptotic NPC-039 cells compared with cells treated with sevoflurane alone. The 
proportion of cells in S- and G0/G1 phases decreased and increased, respectively, when sevoflurane 
concentration was increased from 2 to 10 μM. Incubating NPC-039 cells with sevoflurane also markedly 
reduced levels of cyclin-dependent kinases including p15 INK4B, cyclin D1, p16 INK4A, and CDK-6. In 
contrast, pretreatment with ZVAD-FMK followed by incubation with sevoflurane increased p15 INK4B 
levels. 
Conclusion: Sevoflurane inhibits nasopharyngeal carcinoma cell growth, activating apoptosis and 
inducing cell cycle arrest, thus suggesting its therapeutic potential for the treatment of nasopharyngeal 
carcinoma. 
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Nasopharyngeal carcinoma, which affects the 
head and neck tissues, has a high mortality rate; 
it is most common in Southeast Asia and south 
China [1]. According to a World Health 
Organization (WHO) report, more than 80 % of 
the globally detected cases of nasopharyngeal 
carcinoma occur in China. Nasopharyngeal 
carcinoma is caused by different epidemiological, 
pathological, and virus-related mechanisms, and 
therefore differs from other common cancers of 
the head and neck [2].  
 
At its early stage, the disease is currently treated 
using radiotherapy, but the relapse rate is very 
high, and the 5-year survival rate is very low [3]. 
In most cases, nasopharyngeal carcinoma 
undergoes metastasis to the neck lymph nodes, 
which worsens the prognosis [4]. The risk of 
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treatment failure is nasopharyngeal carcinoma 
metastasizes to distant organs such as the lungs 
and liver [5]. Therefore, physicians are focusing 
on the screening and identification of novel 
therapeutic molecules that can inhibit 
nasopharyngeal carcinoma cell growth. 
 
Sevoflurane is a commonly used anesthetic [6,7]. 
Sevoflurane treatment was found to induce 
apoptosis in alveolar lung carcinoma cells in vitro 
[8]. In addition, pretreating animals with 
sevoflurane prevented injury to various organs 
during ischemia–reperfusion [9, 10]. 
Furthermore, volatile anesthetic compounds 
have been shown to exert anti-inflammatory 
effects both in vitro and in vivo [11,12]. 
 
Mechanistic studies have revealed that 
proinflammatory factors can suppress signal 
transduction pathways [13]. The induction of 
apoptosis via the intrinsic pathway is 
accompanied by reduced mitochondrial 
membrane potential, increased mitochondrial 
membrane permeability, and secretion of 
proapoptotic proteins from the mitochondria to 
the cytosol [14].  
 
The in vitro production of reactive oxygen 
species (ROS) during oxidative stress also 
induces apoptosis via the mitochondrial pathway 
[15]. The present study aimed to evaluate the 
effects of sevoflurane on growth inhibition in 




Chemicals and reagents 
 
Sevoflurane was purchased from Maruishi 
Pharmaceutical Co., Ltd, (Osaka, Japan). 
Annexin V was supplied by Becton Dickinson 
(Franklin Lakes, NJ, USA), and the caspase 
inhibitor Z-VAD was provided by Enzo Life 
Sciences (Plymouth Meeting, PA, USA). The 
disodium salt of 1,2-dihydroxy-3,5-
benzenedisulfonic acid in its monohydrated form 
(Tiron) was supplied by Dojindo Laboratories 
(Kumamoto, Japan). 
 
NPC-039 cell lines and culture 
 
The NPC-039 cell line was purchased from 
ScienCell Research Laboratories (Carlsbad, CA, 
USA) and was cultured in RPMI-1640 medium 
supplemented with 10 % fetal calf serum, 100 
U/mL penicillin, and 100 mg/mL streptomycin. 
The cells were cultured at 37 ˚C in an incubator 
in a humidified atmosphere of 5 % CO2 and 95 % 
air. 
 
Analysis of cell growth 
 
NPC-039 cells were cultured in 96-well plates at 
a density of 2 × 105 cells per well. The cells were 
incubated with 2, 4, 6, 8, and 10 μM sevoflurane 
or DMSO for 48 h. Next, 10 µL of the 
monosodium salt of WST-8 (Wako Chemical, 
Osaka, Japan) was added to each well, and the 
plates were incubated for 6 h in a humidified 
atmosphere of 5 % CO2 and 95 % air at 37 oC. 
The absorbance at 450 nm was then recorded 
using an iMark microplate reader (Bio-Rad, 




Sevoflurane-induced apoptosis in NPC-039 cells 
was analyzed using flow cytometry with annexin 
V and propidium iodide. NPC-039 cells were 
plated in 50-mm culture dishes at a density of 2 × 
106 cells per dish, cultured for 24 h, and then 
treated with 6 µM sevoflurane with or without the 
caspase inhibitor Z-VAD (OMe)-FMK or DMSO 
alone. After incubation, the cells were collected, 
washed twice with ice-cold PBS, and treated with 
1× binding buffer. Then, 10 µL of annexin V and 
PI solution was added to each tube, and the cells 
were incubated in the dark for 20 min. They were 
then treated with binding buffer and analyzed 
using a FACSCalibur flow cytometer and 
CellQuest software (both from Becton 
Dickinson). 
 
Measuring reactive oxygen species levels 
 
ROS levels in sevoflurane-treated NPC-039 cells 
were analyzed using flow cytometry. Briefly, 
NPC-039 cells were either untreated or pre-
treated with the ROS scavenger Tiron, and then 
incubated in six-well plates for 48 h with 
sevoflurane. Then, the cells were treated with 10 
µM 5-(and-6)-chloromethyl-2’,7’-
dichlorodihydro­fluorescein diacetate acetyl ester 
for 45 min, and examined using a FACSCalibur 
flow cytometer and CellQuest software. 
 
Western blotting analysis 
 
NPC-039 cells were plated in 6-mm dishes at a 
density of 3 × 106 cells/dish in DMEM 
supplemented with 10 % FBS. After culture for 
48 h, the cells were treated with sevoflurane for 
48 h and harvested. Lysates were prepared 
using a NucleoSpin® RNA II kit (Macherey-
Nagel, Düren, Germany) as per the 
manufacturer’s protocol. Proteins were separated 
by electrophoresis on 10 % sodium dodecyl 
sulfate–polyacrylamide gels, transferred to 
nitrocellulose membranes (Millipore, Bedford, 
MA, USA), and incubated with primary 
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antibodies; β-actin was used as an endogenous 
control. The primary antibodies against β-actin, 
cyclin-dependent kinases-4 and -6, D1 p15-
INK4B, and p16-INK4A were obtained from Cell 
Signaling Technology (Danvers, MA, USA). 
Antibodies against p-MEK and MEK were 
supplied by Sigma-Aldrich (St. Louis, MO, USA), 
and anti-caspase-3 and -Bax antibodies were 
purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). After overnight 
incubation, the membranes were washed with 
PBS and incubated for 1 h with horseradish 
peroxidase-conjugated anti-rabbit IgG secondary 
antibodies (7074, Cell Signaling Technology). 
Protein–antibody complexes were visualized 
using an ECL plus kit (Amersham Biosciences, 





The data are expressed as mean ± standard 
deviation (SD), and data were analyzed using 
Student's t-tests. P-values  < 0.005 were taken to 




Sevoflurane inhibits growth of NPC-039 cells 
 
WST-8 assays revealed that incubation with 
sevoflurane for 48 h inhibited the growth of NPC-
039 cells. Sevoflurane was added to cultures of 
NPC-039 cells at concentrations of 2, 4, 6, 8 and 
10 μM; the growth inhibition was significant (p < 
0.005) after treatment with ≥ 4 μM sevoflurane 
for 48 h (Figure 1). The median inhibitory 
concentration of sevoflurane on NPC-039 cells 
was 6 μM. 
 
Effect of sevoflurane treatment on NPC-039 
cell apoptosis 
 
After incubation with sevoflurane, cells were 
analyzed for any alterations in their morphology. 
Cells treated with sevoflurane for 24 h exhibited 
prominent nuclear fragmentation and chromatin 
condensation (Figure 2). In addition, increasing 
the treatment duration from 24 to 48 h led to a 
marked increase in the percentage of apoptotic 
NPC-039 cells. 
 
Sevoflurane induced NPC-039 cell apoptosis 
 
The percentage of NPC-039 cells showing signs 
of apoptosis increased from 23.34 to 56.77 % 
when the treatment time as increased from 24 to 
48 h (Figure 3). The annexin V/PI-stained NPC-
039 cell population also increased as the 
treatment time increased from 24 to 48 h (Figure 
3). 
 
Sevoflurane activates caspase-3 and elevates 
ROS levels in NPC-039 cells 
 
NPC-039 cells treated with 6 μM sevoflurane for 
48 h expressed increased levels of Bax and 
cleaved caspase-3 compared with untreated 
cells (Fig. 4A). Reactive oxygen species 
formation was also higher in sevoflurane-treated 
NPC-039 cells after 48 h of treatment (Figure 
4B). Pre-treatment with Z-VAD-FMK (caspase 
inhibitor) for 30 min followed by 48 h incubation 
with 6 μM sevoflurane reduced the population of 
apoptotic NPC-039 cells compared with cells 
treated with sevoflurane alone (Figure 4C). 
Moreover, pretreatment with Tiron (a ROS 
scavenger) followed by incubation with 
sevoflurane also reduced the size of the 
apoptotic NPC-039 cell population (Figure 4C).  
 
 
Figure 1: Sevoflurane inhibits the growth of NPC-039 cells. Cells were incubated with 2, 4, 6, 8 or 10 μM of 
sevoflurane and then analyzed using WST-8 assays. Control cells were incubated with DMSO alone; **p < 0.005 
vs. control cells 
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Figure 2: Morphological alterations in NPC-039 cells following treatment with 6 µM sevoflurane 
 
 
Figure 3: Sevoflurane induces apoptosis in NPC-039 cells. The cells were incubated with 6 μM sevoflurane for 
24 and 48 h and then analyzed by flow cytometry after staining with annexin V/PI. The induction of apoptosis was 
compared in sevoflurane-treated and control NPC-039 cells 
 
 
Figure 4: Sevoflurane treatment activates caspase-3 and Bax and induces ROS production; (A) Western blotting 
was performed after cells were treated with sevoflurane to determine the levels of caspase-3 and Bax; (B) ROS 
production was analyzed in NPC-039 cells that had been incubated with 6 μM sevoflurane with or without 
pretreatment with Z-VAD-FMK; (C) Apoptosis induction was analyzed in NPC-039 cells that had been incubated 
with 6 μM sevoflurane with or without pretreatment with Tiron. Comparisons were made with control cells 
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Sevoflurane induces NPC-039 cell cycle 
arrest 
 
Incubating NPC-039 cells with sevoflurane for 48 
h altered the size of the cell population in various 
phases of the cell cycle. The proportion of cells in 
the S-phase and G0/G1 phase was decreased 
and increased, respectively, by treatment with 
increasing concentrations of sevoflurane (2 to 10 
μM) for 48 h (Figure 5). The population of cells in 
the sub-G1 peak was increased significantly after 
sevoflurane treatment. 
 
Sevoflurane alters expression of CDK and its 
inhibitors 
 
In NPC-039 cells, incubation with sevoflurane for 
48 h markedly reduced the levels of various 
cyclin-dependent kinases including p15 INK4B, 
cyclin D1, and CDK-6 (Figure 6). In contrast, 
pretreating NPC-039 cells with ZVAD-FMK 
followed by incubation with sevoflurane for 48 h 




In the present study, the inhibitory effects of 
sevoflurane on NPC-039 cell growth were 
assessed in vitro. The results revealed that 
sevoflurane significantly inhibited the growth of 
NPC-039 nasopharyngeal carcinoma cells.  
 
Previous studies demonstrated that sevoflurane 
treatment induced apoptosis in vitro in alveolar 
lung carcinoma cells [8]. In the current study, the 
addition of sevoflurane to NPC-039 cells inhibited 
their growth. Further examination of the cells 
revealed that sevoflurane treatment led to 
prominent nuclear fragmentation and chromatin 
condensation. The mechanism by which 
sevoflurane inhibited NPC-039 cell growth was 
also investigated. Flow cytometric analysis of 
NPC-039 cells revealed an increase in the 
percentage of cells with apoptotic characteristics 
from 23.34 to 56.7 % when the treatment 
duration was increased from 24 to 48 h. 
 
Figure 5: Sevoflurane alters the proportion of NPC-039 cells in different phases of the cell cycle. Sevoflurane (2 
to 10 μM) was added to cultures of NPC-039 cells and incubated for 48 h. Flow cytometry was then used to 




Figure 6: Effects of sevoflurane on the levels of cyclin-dependent kinase and its inhibitors. Western blotting was 
used to determine the expression of p15 INK4B, cyclin D1, and CDK-6 in NPC-039 cells after 48 h of treatment 
with sevoflurane. The levels of p15 INK4B were also analyzed after cells were pretreated with ZVAD-FMK 
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The size of the annexin V/PI-stained NPC-039 
cell population also increased when the 
treatment time was increased from 24 to 48 h. 
 
The factors that contribute to the anti-cancer 
properties of chemotherapeutic agents include 
increasing the levels of ROS and p27 [16, 17]. 
The current results showed that NPC-039 cells 
treated with sevoflurane expressed higher levels 
of ROS. Sevoflurane also increased the 
concentrations of Bax and cleaved caspase-3 
compared with untreated cells. However, pre-
treatment with the caspase inhibitor Z-VAD-FMK 
followed by exposure to sevoflurane partly 
reduced the population of apoptotic NPC-039 
cells compared with sevoflurane treatment alone. 
In addition, pretreatment with the ROS 
scavenger Tiron followed by incubation with 
sevoflurane also reduced the apoptotic NPC-039 
cell population. Thus, the present study 
demonstrated that sevoflurane inhibited NPC-
039 cell growth via two pathways. The first 
involves the induction of apoptosis via ROS 
generation and increased caspase-3 and Bax 
levels. The second pathway involves inducing 
cell cycle arrest via the increased expression of 




The ability of sevoflurane to inhibit 
nasopharyngeal carcinoma cell growth by 
activating apoptosis and arresting the cell cycle 
indicates that it is a potent chemotherapeutic 









Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 
article will be borne by them.  
 
Open Access  
 
This is an Open Access article that uses a fund-
ing model which does not charge readers or their 
institutions for access and distributed under the 
terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/ 
4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/rea
d), which permit unrestricted use, distribution, 
and reproduction in any medium, provided the 




1. Chang ET, Adami HO. The enigmatic epidemiology of 
nasopharyngeal carcinoma. Cancer Epidemiol 
Biomarkers Prev 2006; 15: 1765-1777.   
2. Guigay J. Advances in nasopharyngeal carcinoma. Curr 
Opin Oncol 2008; 20: 264-269. 
3. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 
2005; 365: 2041-2054.  
4. Chua DT, Sham JS, Wei WI, Ho WK, Au GK. The 
predictive value of the 1997 American Joint Committee 
on cancer stage classification in determining failure 
patterns in nasopharyngeal carcinoma. Cancer 2001; 
92: 2845-2855.  
5. Cheng SH, Jian JJ, Tsai SY, Chan KY, Yen LK, Chu NM, 
Tan TD, Tsou MH, Huang AT. Prognostic features and 
treatment outcome in locoregionally advanced 
nasopharyngeal carcinoma following concurrent 
chemotherapy and radiotherapy. Int J Radiat Oncol Biol 
Phys 1998; 41: 755-762. 
6. Chandler JR, Myers D, Mehta D, Whyte E, Groberman 
MK, Montgomery CJ, Ansermino JM. Emergence 
delirium in children: a randomized trial to compare total 
intravenous anesthesia with propofol and remifentanil to 
inhalational sevoflurane anesthesia. Paediatr Anaesth 
2013; 23: 309-315.  
7. Bi SS, Deng CH, Zhou TY, Guan Z, Li L, Li HQ, Zhang 
LP, Yang L, Lu W. Remifentanil-sevoflurane interaction 
models of circulatory response to laryngoscopy and 
circulatory depression. Br J Anaesth 2013; 110: 729-
740. 
8. Guui-Hua W, Juan Z,  Da-Qing L,  Zhuo L,  Jing Y,  Nan-
Fu L, Yan G. The common anesthetic, sevoflurane, 
induces apoptosis in A549 lung alveolar epithelial cells. 
Mol Med Rep 2014; 9: 197-203. 
9. Oka M, Hirazawa K, Yamamoto K, Iizuka N, Hazama S, 
Suzuki T, Kobayashi N. Induction of Fas‑mediated 
apoptosis on circulating lymphocytes by surgical stress. 
Ann Surg 1996; 223: 434-440.  
10. Sasajima K, Inokuchi K, Onda M, Miyashita M, Okawa KI, 
Matsutani T, Takubo K: Detection of T cell apoptosis 
after major operations. Eur J Surg 1999; 165: 
1020‑1023. 
11. Giraud O, Seince PF, Rolland C, Lecon-Malas V, 
Desmonts JM, Aubier M, Dehoux M. Halothane reduces 
the early lipopolysaccharide-induced lung inflammation 
in mechanically ventilated rats. Am J Respir Crit Care 
Med 2000; 162: 2278-2286.  
Zhang & Lin 
Trop J Pharm Res, April 2017; 16(4): 793  
 
12. Helmy SA, Al-Attiyah RJ. The effect of halothane and 
isoflurane on plasma cytokine levels. Anaesthesia 2000; 
55: 904-910.  
13. De Rossi LW, Brueckmann M, Rex S, Barderschneider 
M, Buhre W, Rossaint R. Xenon and isoflurane 
differentially modulate lipopolysaccharide-induced 
activation of the nuclear transcription factor κB and 
production of tumor necrosis factor-alpha and 
interleukin-6 in monocytes. Anesth Analg 2004; 98: 
1007-1012. 
14. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Moreno-
Sánchez R. Bioenergetic pathways in tumor 
mitochondria as targets for cancer therapy and the 
importance of the ROS-induced apoptotic trigger. Mol 
Aspects Med 2010; 31: 29-59. 
15. Telser J. Free radicals and antioxidants in normal 
physiological functions and human disease. Int J 
Biochem Cell Biol2007; 39: 44-84. 
16. Akamatsu H, Komura J, Asada Y, Niwa Y. Effects of 
cepharanthin on neutrophil chemotaxis, phagocytosis, 
and reactive oxygen species generation. J Dermatol 
1991; 18: 643-648. 
17. Harada K, Supriatno, Yamamoto S, Kawaguchi S, 
Yoshida H, Sato M. Cepharanthine exerts antitumor 
activity on oral squamous cell carcinoma cell lines by 
induction of p27Kip1. Anticancer Res 2003; 23: 1441-
1448. 
 
